Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

STAT inhibitors for cancer therapy

Authors: Muhammad Furqan, Akintunde Akinleye, Nikhil Mukhi, Varun Mittal, Yamei Chen, Delong Liu

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. This review summarized advances in preclinical and clinical development of these compounds.
Appendix
Available only for authorised users
Literature
1.
Furqan M, Mukhi N, Lee B, Liu D: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 2013, 1 (1): 5-10.1186/2050-7771-1-5.PubMedCentralCrossRefPubMed
2.
Buettner R, Mora LB, Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002, 8 (4): 945-954.PubMed
3.
Weaver AM, Silva CM: Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res. 2007, 9 (6): R79-10.1186/bcr1794.PubMedCentralCrossRefPubMed
4.
Lavecchia A, Di Giovanni C, Novellino E: STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem. 2011, 18 (16): 2359-2375. 10.2174/092986711795843218.CrossRefPubMed
5.
Yu H, Jove R: The STATs of cancer–new molecular targets come of age. Nat Rev Cancer. 2004, 4 (2): 97-105. 10.1038/nrc1275.CrossRefPubMed
6.
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999, 10 (1): 105-115. 10.1016/S1074-7613(00)80011-4.CrossRefPubMed
7.
Ferbeyre G, Moriggl R: The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochimica et Biophysica Acta (BBA)-Reviews on. Cancer. 2011, 1815 (1): 104-114.
8.
Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med. 2004, 10 (8): 789-799. 10.1038/nm1087.CrossRefPubMed
9.
Warsch W, Grundschober E, Sexl V: Adding a new facet to STAT5 in CML: multitasking for leukemic cells. Cell Cycle. 2013, 12 (12): 1813-1814. 10.4161/cc.25116.PubMedCentralCrossRefPubMed
10.
Muller J, Sperl B, Reindl W, Kiessling A, Berg T: Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem. 2008, 9 (5): 723-727. 10.1002/cbic.200700701.CrossRefPubMed
11.
Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R: Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001, 276 (48): 45443-45455. 10.1074/jbc.M107527200.CrossRefPubMed
12.
Ren Z, Cabell LA, Schaefer TS, McMurray JS: Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett. 2003, 13 (4): 633-636. 10.1016/S0960-894X(02)01050-8.CrossRefPubMed
13.
Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004, 3 (3): 261-269.PubMed
14.
Siddiquee KA, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Sebti SM, Jove R, Hamilton AD, Turkson J: An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol. 2007, 2 (12): 787-798. 10.1021/cb7001973.CrossRefPubMed
15.
Chen J, Bai L, Bernard D, Nikolovska-Coleska Z, Gomez C, Zhang J, Yi H, Wang S: Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. ACS Med Chem Lett. 2010, 1 (2): 85-89. 10.1021/ml100010j.PubMedCentralCrossRefPubMed
16.
Coleman DR, Ren Z, Mandal PK, Cameron AG, Dyer GA, Muranjan S, Campbell M, Chen X, McMurray JS: Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J Med Chem. 2005, 48 (21): 6661-6670. 10.1021/jm050513m.CrossRefPubMed
17.
Gomez C, Bai LC, Zhang J, Nikolovska-Coleska Z, Chen JY, Yi H, Wang SM: Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. Bioorg Med Chem Lett. 2009, 19 (6): 1733-1736. 10.1016/j.bmcl.2009.01.091.CrossRefPubMed
18.
Mandal PK, Heard PA, Ren ZY, Chen XM, McMurray JS: Solid-phase synthesis of Stat3 inhibitors incorporating O-carbamoylserine and O-carbamoylthreonine as glutamine mimics. Bioorg Med Chem Lett. 2007, 17 (3): 654-656. 10.1016/j.bmcl.2006.10.099.PubMedCentralCrossRefPubMed
19.
Mandal PK, Limbrick D, Coleman DR, Dyer GA, Ren Z, Birtwistle JS, Xiong C, Chen X, Briggs JM, McMurray JS: Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling. J Med Chem. 2009, 52 (8): 2429-2442. 10.1021/jm801491w.PubMedCentralCrossRefPubMed
20.
Schust J, Sperl B, Hollis A, Mayer TU, Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006, 13 (11): 1235-1242. 10.1016/j.chembiol.2006.09.018.CrossRefPubMed
21.
Sanseverino I, Purificato C, Gauzzi MC, Gessani S: Revisiting the specificity of small molecule inhibitors: the example of stattic in dendritic cells. Chem Biol. 2012, 19 (10): 1213-1214. 10.1016/j.chembiol.2012.08.021. author reply 1215–1216CrossRefPubMed
22.
Chen CL, Loy A, Cen L, Chan C, Hsieh FC, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K: Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer. 2007, 7: 111-10.1186/1471-2407-7-111.PubMedCentralCrossRefPubMed
23.
Song H, Wang RX, Wang SM, Lin J: A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA. 2005, 102 (13): 4700-4705. 10.1073/pnas.0409894102.PubMedCentralCrossRefPubMed
24.
Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, Bhasin D, Regan N, Lin L, Chan C: LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer. 2009, 100 (1): 106-112. 10.1038/sj.bjc.6604793.PubMedCentralCrossRefPubMed
25.
Mencalha AL, Du Rocher B, Salles D, Binato R, Abdelhay E: LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemother Pharmacol. 2010, 65 (6): 1039-1046. 10.1007/s00280-009-1109-3.CrossRefPubMed
26.
Ball S, Li C, Li PK, Lin J: The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PLoS One. 2011, 6 (4): e18820-10.1371/journal.pone.0018820.PubMedCentralCrossRefPubMed
27.
Lin L, Benson DM, DeAngelis S, Bakan CE, Li PK, Li C, Lin J: A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int J Cancer. 2012, 130 (6): 1459-1469. 10.1002/ijc.26152.PubMedCentralCrossRefPubMed
28.
Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 2010, 12 (1): 39-50.PubMedCentralCrossRefPubMed
29.
Liu A, Liu Y, Jin Z, Hu Q, Lin L, Jou D, Yang J, Xu Z, Wang H, Li C: XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS One. 2012, 7 (10): e46624-10.1371/journal.pone.0046624.PubMedCentralCrossRefPubMed
30.
Liu A, Liu Y, Xu Z, Yu W, Wang H, Li C, Lin J: Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells. Cancer Sci. 2011, 102 (7): 1381-1387. 10.1111/j.1349-7006.2011.01932.x.CrossRefPubMed
31.
Liu Y, Liu A, Xu Z, Yu W, Wang H, Li C, Lin J: XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Apoptosis. 2011, 16 (5): 502-510. 10.1007/s10495-011-0578-0.CrossRefPubMed
32.
Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip MLR, Jove R, McLaughlin MM, Lawrence NJ: Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA. 2007, 104 (18): 7391-7396. 10.1073/pnas.0609757104.PubMedCentralCrossRefPubMed
33.
Fletcher S, Singh J, Zhang X, Yue PB, Page BDG, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J: Disruption of transcriptionally active Stat3 dimers with Non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem. 2009, 10 (12): 1959-1964. 10.1002/cbic.200900172.PubMedCentralCrossRefPubMed
34.
Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J: A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010, 79 (10): 1398-1409. 10.1016/j.bcp.2010.01.001.PubMedCentralCrossRefPubMed
35.
Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD: Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett. 2011, 21 (18): 5605-5609. 10.1016/j.bmcl.2011.06.056.PubMedCentralCrossRefPubMed
36.
Matsuno K, Masuda Y, Uehara Y, Sato H, Muroya A, Takahashi O, Yokotagawa T, Furuya T, Okawara T, Otsuka M: Identification of a new series of STAT3 inhibitors by virtual screening. ACS Med Chem Lett. 2010, 1 (8): 371-375. 10.1021/ml1000273.PubMedCentralCrossRefPubMed
37.
Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM: Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009, 69 (1): 193-202. 10.1158/0008-5472.CAN-08-2575.CrossRefPubMed
38.
Gupta SC, Patchva S, Aggarwal BB: Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013, 15 (1): 195-218. 10.1208/s12248-012-9432-8.PubMedCentralCrossRefPubMed
39.
Roy S, Levi E, Majumdar A, Sarkar F: Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012, 5 (1): 58-10.1186/1756-8722-5-58.PubMedCentralCrossRefPubMed
40.
Lin L, Deangelis S, Foust E, Fuchs J, Li CL, Li PK, Schwartz EB, Lesinski GB, Benson D, Lu JG: A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer. 2010, 9: 217-10.1186/1476-4598-9-217.PubMedCentralCrossRefPubMed
41.
Lin L, Hutzen B, Ball S, Foust E, Sobo M, Deangelis S, Pandit B, Friedman L, Li CL, Li PK: New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci. 2009, 100 (9): 1719-1727. 10.1111/j.1349-7006.2009.01220.x.CrossRefPubMed
42.
Lin L, Hutzen B, Zuo MX, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S: Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010, 70 (6): 2445-2454. 10.1158/0008-5472.CAN-09-2468.PubMedCentralCrossRefPubMed
43.
Liu Y, Fuchs J, Li CL, Lin JY: IL-6, a risk factor for hepatocellular carcinoma FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle. 2010, 9 (17): 3423-3427. 10.4161/cc.9.17.12946.CrossRefPubMed
44.
Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin JY, Fuchs JR, Light E, Bradford CR, Prince MEP: Sensitization of head and neck cancer to cisplatin through the Use of a novel curcumin analog. Arch Otolaryngol Head Neck Surg. 2011, 137 (5): 499-507. 10.1001/archoto.2011.63.PubMedCentralCrossRefPubMed
45.
Bill MA, Nicholas C, Mace TA, Etter JP, Li CL, Schwartz EB, Fuchs JR, Young GS, Lin L, Lin JY: Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS One. 2012, 7 (8): e40724-10.1371/journal.pone.0040724.PubMedCentralCrossRefPubMed
46.
Onimoe GI, Liu AG, Lin L, Wei CC, Schwartz EB, Bhasin D, Li CL, Fuchs JR, Li PK, Houghton P: Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012, 30 (3): 916-926. 10.1007/s10637-011-9645-1.CrossRefPubMed
47.
Wei CC, Ball S, Lin L, Liu AG, Fuchs JR, Li PK, Li CL, Lin JY: Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells. Int J Oncol. 2011, 38 (1): 279-285.PubMed
48.
Xu X, Kasembeli MM, Jiang XQ, Tweardy BJ, Tweardy DJ: Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One. 2009, 4 (3): e4783-10.1371/journal.pone.0004783.PubMedCentralCrossRefPubMed
49.
Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ: Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011, 117 (21): 5701-5709. 10.1182/blood-2010-04-280123.PubMedCentralCrossRefPubMed
50.
Yu WY, Xiao H, Lin JY, Li CL: Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem. 2013, 56 (11): 4402-4412. 10.1021/jm400080c.CrossRefPubMed
51.
Muller J, Schust J, Berg T: A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization. Anal Biochem. 2008, 375 (2): 249-254. 10.1016/j.ab.2008.01.017.CrossRefPubMed
52.
Page BDG, Khoury H, Laister RC, Fletcher S, Vellozo M, Manzoli A, Yue PB, Turkson J, Minden MD, Gunning PT: Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem. 2012, 55 (3): 1047-1055. 10.1021/jm200720n.CrossRefPubMed
53.
Turkson J, Zhang SM, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R: Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther. 2004, 3 (12): 1533-1542.PubMed
54.
Turkson J, Zhang SM, Mora LB, Burns A, Sebti S, Jove R: A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem. 2005, 280 (38): 32979-32988. 10.1074/jbc.M502694200.CrossRefPubMed
55.
Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O, Bjartell A: Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate. 2008, 68 (3): 269-280. 10.1002/pros.20699.CrossRefPubMed
56.
Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T: Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012, 149 (1): 214-231. 10.1016/j.cell.2012.02.013.PubMedCentralCrossRefPubMed
57.
Muller S, Filippakopoulos P, Knapp S: Bromodomains as therapeutic targets. Expert Rev Mol Med. 2011, 13: 1-21.CrossRef
58.
Liu SH, Walker S, Nelson E, Cirulli R, Xiang M, Qi J, Bradner JE, Frank D: Targeting STAT5 in leukemia through inhibition of bromodomain proteins. Blood. 2012, 120 (21): abstr#399-
59.
Gu J, Li G, Sun T, Su Y, Zhang X, Shen J, Tian Z, Zhang J: Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol. 2008, 89 (1): 9-17. 10.1007/s11060-008-9590-9.CrossRefPubMed
60.
Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi SC, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA. 2003, 100 (7): 4138-4143. 10.1073/pnas.0534764100.PubMedCentralCrossRefPubMed
61.
Souissi I, Ladam P, Cognet JAH, Le Coquil S, Varin-Blank N, Baran-Marszak F, Metelev V, Fagard R: A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Mol Cancer. 2012, 11: 12-10.1186/1476-4598-11-12.PubMedCentralCrossRefPubMed
62.
Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, Roger C, Dusanter-Fourt I, Varin-Blank N, Cao A: A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-kappaB. BMC Cell Biol. 2011, 12: 14-10.1186/1471-2121-12-14.PubMedCentralCrossRefPubMed
63.
Zhang X, Zhang J, Wang L, Wei H, Tian Z: Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer. 2007, 7: 149-10.1186/1471-2407-7-149.PubMedCentralCrossRefPubMed
64.
Wang X, Zeng J, Shi M, Zhao S, Bai W, Cao W, Tu Z, Huang Z, Feng W: Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth. DNA Cell Biol. 2011, 30 (2): 71-78. 10.1089/dna.2010.1112.PubMedCentralCrossRefPubMed
65.
Tomita N, Kashihara N, Morishita R: Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease. Clin Exp Nephrol. 2007, 11 (1): 7-17. 10.1007/s10157-007-0459-6.CrossRefPubMed
66.
Tomita N, Ogihara T, Morishita R: Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design. Curr Drug Targets. 2003, 4 (8): 603-608. 10.2174/1389450033490803.CrossRefPubMed
67.
Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KAB, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP: Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2009, 63 (6): 983-995. 10.1007/s00280-008-0823-6.PubMedCentralCrossRefPubMed
68.
McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagener G, Chasan-Taber S: Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012, 7 (11): e49006-10.1371/journal.pone.0049006.PubMedCentralCrossRefPubMed
69.
Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M: Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012, 126 (19): 2283-2292. 10.1161/CIRCULATIONAHA.112.104125.CrossRefPubMed
70.
Hong DS, Younes A, Fayad L, Fowler NH, Hagemeister FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, Yamashita M: A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol. 2013, 31 (suppl): 8523-
71.
Rao DD, Vorhies JS, Senzer N, Nemunaitis J: SiRNA vs. ShRNA: similarities and differences. Adv Drug Deliv Rev. 2009, 61 (9): 746-759. 10.1016/j.addr.2009.04.004.CrossRefPubMed
72.
Kaymaz BT, Selvi N, Gunduz C, Aktan C, Dalmizrak A, Saydam G, Kosova B: Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Ann Hematol. 2013, 92 (2): 151-162. 10.1007/s00277-012-1575-2.CrossRefPubMed
73.
Klosek SK, Nakashiro KC, Hara S, Goda H, Hamakawa H: Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma. Oncol Rep. 2008, 20 (4): 873-878.PubMed
74.
Konnikova L, Kotecki M, Kruger MM, Cochran BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer. 2003, 3: 23-10.1186/1471-2407-3-23.PubMedCentralCrossRefPubMed
75.
Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS: Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol. 2009, 34 (5): 1209-1220.PubMedCentralPubMed
76.
Ma YL, Kowolik CM, Swiderski PM, Kortylewski M, Yu H, Horne DA, Jove R, Caballero OL, Simpson AJG, Lee FT: Humanized Lewis-Y Specific Antibody Based Delivery of STAT3 siRNA. ACS Chem Biol. 2011, 6 (9): 962-970. 10.1021/cb200176v.CrossRefPubMed
77.
Verma NK, Davies AM, Long A, Kelleher D, Volkov Y: STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell Mol Biol Lett. 2010, 15 (2): 342-355. 10.2478/s11658-010-0008-2.CrossRefPubMed
78.
Lu YM, Zhang SL, Meng LR, Zhao YY: Influence of human epidermal growth factor receptor-2 siRNA on chemosensitivity to cisplatin of human ovarian carcinoma cells: an in vitro experiment. Zhonghua Yi Xue Za Zhi. 2008, 88 (13): 909-913.PubMed
79.
Yang Z, Cai JH, Xie SJ, Li GX, Song WQ, Yan QH, Yan L, Zhang F: Therapeutic effects of signal transducer and activator of transcription 3 siRNA on human breast cancer in xenograft mice. Chin Med J (Engl). 2011, 124 (12): 1854-1861.
80.
Zhang L, Zhao Z, Feng Z, Yin N, Lu G, Shan B: RNA interference-mediated silencing of Stat5 induces apoptosis and growth suppression of hepatocellular carcinoma cells. Neoplasma. 2012, 59 (3): 302-309. 10.4149/neo_2012_039.CrossRefPubMed
81.
Moser C, Ruemmele P, Gehmert S, Schenk H, Kreutz MP, Mycielska ME, Hackl C, Kroemer A, Schnitzbauer AA, Stoeltzing O: STAT5b As molecular target in pancreatic cancer-inhibition of tumor growth, angiogenesis, and metastases. Neoplasia. 2012, 14 (10): 915-925.PubMedCentralCrossRefPubMed
82.
Jing NJ, Li YD, Xiong WJ, Sha W, Jing L, Tweardy DJ: G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 2004, 64 (18): 6603-6609. 10.1158/0008-5472.CAN-03-4041.CrossRefPubMed
83.
Reddy KR, Guan Y, Qin G, Zhou Z, Jing N: Combined treatment targeting HIF-1alpha and Stat3 is a potent strategy for prostate cancer therapy. Prostate. 2011, 71 (16): 1796-1809. 10.1002/pros.21397.CrossRefPubMed
84.
Weerasinghe P, Li YF, Guan YL, Zhang RW, Tweardy DJ, Jing NJ: T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate. 2008, 68 (13): 1430-1442. 10.1002/pros.20807.PubMedCentralCrossRefPubMed
85.
86.
Firer M, Gellerman G: Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012, 5 (1): 70-10.1186/1756-8722-5-70.PubMedCentralCrossRefPubMed
87.
Wang K, Wei G, Liu D: CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012, 1 (1): 36-10.1186/2162-3619-1-36.PubMedCentralCrossRefPubMed
88.
Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H: Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. J Hematol Oncol. 2012, 5 (1): 16-10.1186/1756-8722-5-16.PubMedCentralCrossRefPubMed
89.
Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath S, Liu D: Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol. 2012, 5 (1): 21-10.1186/1756-8722-5-21.PubMedCentralCrossRefPubMed
90.
Lamba G, Gupta R, Lee B, Ambrale S, Liu D: Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol. 2012, 1 (1): 14-10.1186/2162-3619-1-14.PubMedCentralCrossRefPubMed
91.
92.
93.
Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S: Splenomegaly in myelofibrosis–new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 2012, 5 (1): 43-10.1186/1756-8722-5-43.PubMedCentralCrossRefPubMed
Metadata
Title
STAT inhibitors for cancer therapy
Authors
Muhammad Furqan
Akintunde Akinleye
Nikhil Mukhi
Varun Mittal
Yamei Chen
Delong Liu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-90

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue

Research

Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy

Research

Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement

Rapid communication

A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors

Research

Activated N-Ras signaling regulates arterial-venous specification in zebrafish

Research

Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition

Research

Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits